Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial